The dopamine D 3 receptor gene (DRD3) is a candidate for a number of psychiatric conditions including schizophrenia, bipolar disorder and alcohol and drug abuse. Previous studies have reported associations between polymorphisms in DRD3 and these disorders, but these findings may have reflected linkage disequilibrium with pathogenic variants that are further upstream. We have isolated and sequenced approximately 9 kb of genomic sequence upstream of the human DRD3 translational start site. Using 5Ј RACE, we have identified within this region three additional exons and two putative promoter regions which show promoter activity in three different cell lines. A 5Ј UTR identified only in lymphoblasts is spread over three exons and is 353 bp long. A second 5Ј UTR, found in adult and fetal brain, lymphocytes, kidney and placenta is spread over two exons and is 516 bp long. A 260-bp sequence within this 9 kb corresponds to a previously reported EST, but corresponding mRNA could not be found in the tissues above. The EST, 5Ј UTRs and putative promoter regions have been analysed for polymorphisms, revealing 10 single nucleotide polymorphisms, seven of which were tested for association in a large sample of unrelated patients with schizophrenia and matched controls. No associations were observed with schizophrenia. In addition we failed to replicate previous findings of association with homozygosity of the Ser9Gly variant. The results from this study imply that neither the coding nor the regulatory region of DRD3 plays a major role in predisposition to schizophrenia.
Introduction
The D 3 dopamine receptor gene (DRD3) has been implicated by association studies as a possible candidate for a number of neuropsychiatric disorders and phenotypes including schizophrenia, bipolar disorder, Tourette syndrome, and substance abuse. 1 The phenotype most intensively investigated in connection with DRD3 is schizophrenia, and since the original report of association 2 there have been more than 24 independent follow-up studies of a non-synonymous A/G polymorphism (Ser9Gly) in exon 1. Although the results of these have been mixed, a meta-analysis concluded in favour of association between homozygosity at this site and schizophrenia. 3 However, the Ser9Gly polymorphism is conservative and does not lie within the regions of the receptor thought to be involved in ligand binding or signal transduction. Moreover, functional 4 The DRD3 gene locus, 3q13.3, is not a region where significant linkage has been reported in schizophrenia. However, these findings raise the possibility that the Ser9Gly variant is in linkage disequilibrium (LD) with one or more susceptibility variants elsewhere in the gene. Previous mutation screens of DRD3 have failed to reveal potentially functional polymorphisms in the coding region that could account for the association data. 5 However these studies were limited by incomplete knowledge of the structure of DRD3, and in particular by the fact that the DRD3 promoters had yet to be identified. Prior to this study, the DRD3 cDNA was believed to consist of six exons (total length 1.2 kb) and five introns (total length Ͼ 45 kb). However, neither the extent of the 5Ј UTR nor the location of the promoter(s) were known. An additional 1724 bp of 5Ј flanking sequence has been recently reported but no gene structure has been attributed to this. 6 In the present study we used 5Ј RACE to determine the sequence of the 5Ј UTR of DRD3 in several different tissues. By sequencing genomic clones, we have obtained a contiguous genomic sequence containing three previously unknown exons which give rise to two alternative mRNAs transcribed from two different putative promoters. We then confirmed the function of the putative promoters by luciferase reporter gene assays. Finally, we searched the putative promoter regions, the exons and flanking intronic regions for novel polymorphisms and carried out association studies between these, the Ser9Gly polymorphism, and schizophrenia in a large case control sample.
Materials and methods
Characterising 5Ј UTR Poly A+ RNA was prepared from human lymphoblasts and lymphocytes using standard procedures. Human kidney, placental, fetal brain and adult brain mRNA samples were purchased commercially (Clontech, Palo Alto, CA, USA). 5Ј RACE was performed using three nested antisense primers to the first known exon of DRD3 (SP1: agtaggagagggcatagtag; SP2: gcacctgtgg agttctctg; SP3: tgtagttcaggtggctactc) using the protocols provided with the RACE kit (Boehringer Mannheim). First strand cDNA was synthesised from total RNA using SP1 and purified using the Boehringer Mannheim High Pure PCR purification kit. A homopolymeric A-tail was then added to the 3Ј ends of the cDNA using terminal transferase. Tailed cDNA was then used as a template for PCR using primer SP2 and an anchored oligo dT primer (gaccacgcgtatcgatg tcgacttttttttttttttttv). The product of this round of PCR was then re-amplified using primer SP3, and a sense primer comprising the anchor sequence of the anchored oligo dT primer (gaccacgcgtatcgatgtcgac). Good quality RACE products were separated by agarose gel electrophoresis and the resulting bands were then extracted from the gel. Each product was ligated into pGEM T vector and used to transform XL1blue cells. Clones containing the insert were purified and sequenced using primers corresponding to the plasmid, using BigDye chemistry (ABI). Additional 5Ј RACE experiments were carried out using primers closer to the 5Ј end of the new sequence in order to confirm the 5Ј end of the mRNA.
Isolation and sequencing of genomic clones
A gridded human PAC library 7 obtained from the UK HGMP Resource Centre was screened using a 5Ј end labelled oligonucleotide (cctggctggcacctgtggag ttctctgccccac) corresponding to bases 44-76 of the coding region of DRD3. Four independent clones were isolated (34e22, 119p1, 138e21, 221m4). Clone 138e21 contained sequence previously designated as exon 1 and an additional 90 kb of 5Ј sequence. A total of 9.3 kb of PAC sequence in a 5Ј direction from the 5Ј end of the known coding region was obtained directly from the purified PAC DNA using BigDye chemistry (ABI) by incrementally designing a series of primers representing the 5Ј boundary of known genomic sequence. The same primers were also used to amplify and sequence human genomic DNA to confirm that the PAC clone did not contain rearrangements (data not shown). This sequence has been deposited in the EMBL Nucleotide Sequence Database-accession No. AJ271348.
Promoter analysis 5Ј RACE analysis (above) indicated two distinct starts of transcription (see Figure 1) . To confirm this, approximately 500 bp of genomic sequence 5Ј to both putative starts of transcription were tested for promoter activity in a reporter gene assay. Primers were designed to amplify bases 1300-1945 and bases 2306-2860 (from accession No. AJ271348). Primers for the lymphoblast promoter were forward: gttgcttgggtatgtctgctg and reverse: gtctctgctgggaataattgga. Primers for the promoter seen in the other tissues were forward: gcacatccactgttggcagag and reverse: gttttctcctcagtgctctttt.
Following PCR with Expand High-Fidelity DNA polymerase (Roche), 15 ng of amplimers representing each putative promoter were ligated into a pGL3 basic vector (Promega) modified for T/A cloning (manuscript in preparation). Clones containing the insert were sequenced to confirm their fidelity prior to transfection into three human cell lines originating from tissue known to express the dopamine D3 receptor: HEK293t (human embryo kidney), TE671 (human meduloblastoma) and JEG-3 (human placenta) obtained from the European Collection of Cell Cultures (ECACC). Cell lines were cultured according to ECACC specifications at 37°C with 5% CO 2 . Cells were seeded into black, clear bottomed 96-well luminometric plates (Perkin Elmer) at 60% confluencey the day prior to transfection. HEK293t cells were transfected with 40 ng well 
PLUS-reagent.
Cell lines were transfected overnight in serum-free medium which was replaced with complete medium and incubated for a further 24 h. Luciferase activity was measured using a Luc Screen assaying kit (Tropix). Plates were read on a TR717 scintillation counting luminometer (Bertoldt).
Mutation analysis
A total of 4750 bp of genomic sequence was screened for mutations (Figure 1 ), including all novel exonic sequences and flanking intronic and 5Ј flanking/ promoter regions. The primers and fragment sizes are detailed in Table 1 . The sample for mutation screening consisted of 14 unrelated subjects meeting DSM-IV criteria for schizophrenia and 14 subjects meeting DSM-IV criteria for bipolar disorder. All were unrelated British Caucasians born in the UK. Our screening sample for mutation detection contains equal numbers of subjects with schizophrenia and bipolar disorder because our extended research group is interested in both disorders. This decision has little impact on our estimates of power to detect susceptibility alleles for schizophrenia except those with extremely low frequencies. Table 1 Primers used for mutational analysis of the human dopamine D 3 receptor gene. The base pairs shown represent the first and last which were screened for polymorphisms using these primers. The numbering system starts at the translational start site
Under the null hypothesis, alleles in our screening sample will simply be representative of general population allele frequencies. Our sample will therefore have power of 0.8 to detect polymorphisms occurring in the general population with a frequency of 0.03. On the other hand, if the hypothesis is correct, that is alleles of DRD3 are associated with schizophrenia, at least half of our sample will be enriched for susceptibility alleles and therefore this degree of power will be maintained for alleles of even lower frequency. We would also note that because of the huge discordance in their allele frequencies, it is extremely unlikely that alleles with frequencies in this range (Ͻ0.03) would permit association to be detected at the Bal1 site by virtue of LD. Denaturing high performance liquid chromatography Molecular Psychiatry (DHPLC) was performed at a minimum of two temperatures as described in detail elsewhere 8 using a WAVE DNA fragment analyser (Transgenomic, Santa Clara, CA, USA). Where DHPLC analysis suggested that a subject was heterozygous, the PCR products from that individual were sequenced to determine the nature of the polymorphism using the Big Dye Terminator Cycle Sequencing Kit (Perkin Elmer Applied Biosystems, Cheshire, UK) as described by the manufacturer.
Case control samples
The case control study was undertaken using 368 unrelated Caucasians (266 males and 102 females, age 46 ± 13 years) born in the UK or Ireland/Eire meeting DSM-IV 9 criteria for schizophrenia, and 368 control subjects (266 males and 102 females average age 43 ± 12 years).
Molecular Psychiatry
Diagnoses were determined following a semi-structured interview and examination of case notes as described. 10 Local Research Ethics Committee approval was obtained, and subjects gave written informed consent to participate. The control individuals were group matched to probands for age, sex, and ethnicity from more than 1400 blood donors recruited from the local branch of the National Blood Transfusion Service (Wales). Controls were not specifically screened for the absence of psychiatric illness, although the policy of the National Blood Transfusion Service is to not receive donations from individuals who are on medication.
Genotyping
During the course of this study, an independent publication by Ishiguro et al (2000) 11 reported 800 bp of 5Ј DRD3 flanking region, and a significant association between DRD3 haplotypes and schizophrenia. Two of the SNPs studied, in conjunction with Ser9Gly, resulted in a highly significant association. The two SNPs (−712G/C and −205A/G) were independently identified in our study (our nomenclature being −710G/C and −203A/G). These two SNPs along with the Ser9Gly polymorphism were genotyped using the restriction fragment polymorphism (RFLP) method after PCR amplification. The primers, conditions and restriction enzymes are shown in Table 2 . The primers and restriction conditions for the −710 G/C and −203 A/G polymorphisms are the same as those used by Ishiguro et al. 11 Fragments were separated on either 1.6% agarose or 1% agarose : 2% metaphore gels and visualised by ethidium bromide staining and ultraviolet transillumination.
A further three upstream SNPs (−2249A/G, −4147C/T, −6733G/A) and a recently reported coding SNP (alanine 38 threonine) 11 were genotyped in a subset of the case/control sample (184 patients, 184 
#Numbering of SNP relates to the position relative to the start of translation. The bases in bold indicate that a mismatched primer was used to introduce a restriction enzyme cut site to identify the polymorphism. *Serine-9-Glycine polymorphism.
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**Alanine-38-Threonine polymorphism.
11 controls). The details of the primers, conditions and RFLP assay are also shown in Table 2 . These SNPs were selected to permit LD analysis of the region based upon conservative estimates of LD in outbred populations. 12 
Statistics
Genotypic and allelic association was tested by 2 . Haplotypes were assigned using EH+ 13, 14 (http:// linkage.rockefeller.edu/ott/eh.htm). The 'Ldmax' option of the 'Gold' package (http://www.well.ox. ac.uk/ssthma/GOLD/) was used to estimate DЈ.
Results
To allow comparison with previous data, we continue to refer to the previously reported most 5Ј exon as exon 1. The novel exons reported here are referred to as exons A, B and C. Exon A is the most 5Ј whilst exon C is the most 3Ј.
Structure and sequence of 5Ј region of DRD3
A contiguous sequence of approximately 9 kb (EMBL accession No. AJ271348) was derived from PAC clone 138e21. 5Ј RACE of lymphoblast RNA yielded a single product. The sequence is given in Figure 2a .
Comparison with the PAC sequence revealed that the genomic sequence encoding this UTR contains two introns. The UTR is thus encoded by 105 bp of exon 1 and two additional exons of 269 bp (exon C) and 49 bp (exon B) separated by introns of 3826 and 1950 bp respectively (Figure 1) . 5Ј RACE from several other tissues (adult brain, fetal brain, placenta, kidney and lymphocyte) yielded a product of approximately 500 bp. Subsequent 5Ј RACE experiments using new primers 5Ј to SP3 extended the 5Ј UTR, yielding a total 5Ј UTR in these tissues of 587 bases. This is encoded by 105 bp of exon 1 and an Figure 1 .
Comparison of the genomic sequence with various sequence databases identified a previously reported EST (accession number: D81856) obtained from a fetal brain library. 15 This lies between exon C and exon 1. We attempted to PCR between the EST and each of the newly identified exons as well as exons 1 and 2, using both lymphoblast and fetal brain mRNA under a range of PCR conditions. None of these experiments gave a product. PCR analysis of all the cDNA samples described above using primers corresponding to the EST also gave no product. Finally, 3Ј RACE was attempted using lymphoblast and fetal brain mRNA with nested primers within this EST, but again no product could be obtained. The failure of these experiMolecular Psychiatry ments, while not conclusive, suggests that this EST sequence is not represented in dopamine D 3 receptor mRNA and may not be transcribed at all.
Promoter analysis
The relative promoter activities of the two 5Ј flanking sequences are shown in Table 3 along with PGL3-SV40 positive control and the promoterless pGL3 basic negative control. Both sequences had much greater activity than pGL3 basic. The lymphoblast promoter drove luciferase transcription significantly higher than the alternative promoter in all three cell lines.
Mutation and association analysis
Ten polymorphisms were found. These are shown in Figure 1 . Table 4 presents the data from association analysis of the two 5Ј upstream region polymorphisms; −712G/C, −203G/A, and the exon 1 coding polymorphism (Ser9Gly) in the 368 schizophrenia case/control sample. There was no significant disease association with any of the alleles of the three markers studied. There were more heterozygotes for the Ser9Gly polymorphism in the patient sample ( 2 = 3.998, P Ͻ 0.05) and this was reflected by the fact that the patient sample was found to be significantly out of Hardy-Weinberg equilibrium ( 2 = 4.94, P Ͻ 0.026). An excess of heterozygotes could occur through partial enzyme digestion causing the miscalling of a Gly/Gly homozygote (fully digested) as a Ser/Gly heterozygote. However the amplimere produced in our assay has a common Bal1/Msc1 cut site in addition to the cut site introduced by the A/G polymorphism that results in the serine to glycine amino acid change. Therefore any partial digests producing ambiguous heterozygotes would also be seen as partial digests of the common cut site-this was not seen. Half of the sample was regenotyped and this confirmed that deviation from Hardy-Weinberg equilibrium was not a result of genotyping error.
Using the statistical package EH+, we attempted to replicate the haplotypic analysis 11 (Table 5) . No significant difference was found in the frequencies of three marker (or two marker; data not shown) haplotypes between the cases and the controls (P = 0.2150).
A further four polymorphisms were studied in a subset of the full sample. These were −6733G/A, −4147C/T, −2249G/A polymorphisms and a previously reported A38T missense mutation in exon 1 11 (Table  6 ). All markers were in Hardy-Weinberg equilibrium. There was no significant genotypic or allelic association with schizophrenia.
Finally, LD max (Gold package) was used to assess the extent of linkage disequilibrium (DЈ) between the Ser9Gly polymorphism and six other SNPs extending up to almost 7 kb upstream of the Ser9Gly polymorphism. Calculations of DЈ between all permutations of the −203, −710 and Ser9Gly variants are shown in Table 7 . 24 Parkinson's disease 25 and others. In most cases the results have been inconclusive, partly due to small subject numbers. However, in schizophrenia, a meta-analysis of the available world literature demonstrated a small excess of homozygosity of the Ser9Gly polymorphism. 3 Given an absence of a demonstrated functional effect for the Bal I polymorphism (Ser9Gly) , we postulated that excess homozygosity in schizophrenia might reflect linkage disequilibrium with a true susceptibility variant or variants polymorphism. In order to test this hypothesis, we sought to clarify the structure of the 5Ј flanking region, screen for novel mutations and try to replicate the findings of Ishiguro et al 11 who found an association with a three marker haplotype in the 5Ј upstream region of DRD3.
Discussion
Using a combination of 5Ј RACE and genomic sequencing, we have identified three novel 5Ј exons for DRD3 and have also identified the 5Ј end of exon 1. We have also identified two alternative mRNA species designated lymphoblast and brain ( Figure 1 ). Each is encoded by a different terminal 5Ј exon which suggest that they are derived from alternative promoters rather than alternative splicing. This interpretation is supported by our observation that both 5Ј sequences immediately adjacent to both putative transcriptional start sites drive transcription to a significantly greater extent than pGL3 basic negative control (Table 3) .
While we can be confident that both transcripts represent alternative promoter activity experimentally, it is not clear that both transcripts occur in vivo because one of the transcripts was only found in lymphoblastoid cell lines. This leaves open the possibility that transformation and culture of lymphoblasts permits transcription from a cryptic promoter that is not used in vivo. However, the putative transcription start-site for this transcript has high homology to the 5Ј-YYCAYYYYY-3Ј consensus. 26 Also, an analysis of the sequence immediately upstream of exon B (the lymphoblast expressed first exon) reveals a TATA consensus sequence approximately 30 bp upstream and CAAT motifs further upstream. The sequence immediately upstream of exon A does not contain these elements. However, eukaryotic promoters are known to be highly diverse and difficult to predict from sequence data alone. 27 The position of the EST between exons C and 1 of the DRD3 initially suggested to us that it may be an exon of another variant DRD3 mRNA species. However, we have not been able to identify any DRD3 cDNA sequence contiguous to the EST which suggests that either it is not part of DRD3, or possibly is not transcribed at all. However, negative PCR reactions cannot exclude the above possibility and it is possible therefore, that this sequence represents either a minor transcript, or one which is transcribed under conditions that are not found in the source tissue of our samples.
Having clarified the 5Ј structure of DRD3, we screened this region for polymorphisms using DHPLC *Because of small cell sizes, simulated P values were estimated using CLUMP. 30 None of the comparisons in Table 6 were significant. This sample has greater than 80% power to detect variants with a frequency of 0.03 or more. Ten variants were found of which three had been previously reported. We selected two of the SNPs (−710g/c, −203g/a) in addition to the Ser9Gly polymorphism for genotyping in a sample of 368 cases and controls because haplotypes created with these markers had previously been associated with schizophrenia in a Japanese population. Note that this sample does not overlap with previous publications on DRD3 from our group. 3 In contrast to our previous findings and that of the meta-analysis 3 we did not find evidence for association between schizophrenia and homozygosity at the Ser9Gly polymorphism. In fact we found the converse, with extremely modest evidence for an excess of heterozygotes in the patient population compared both with controls ( 2 = 4, 1 df, P = 0.045) and with HWE. Given that in the extensive DRD3 literature, there is no support for a finding in this direction, we suggest that this result is attributable to chance rather than true association. We would also note that although the sample is the biggest single sample in which the DRD3 polymorphism has been analysed to date, it is still small compared with that required to have high power for replication. 28 Nevertheless, it is surprising that we did not at least find a non-significant trend towards homozygosity, and the observation that the limit of the 95% confidence interval (0.5530-0.994) in our sample for an excess of homozygotes, at least casts considerable doubt about the homozygosity hypothesis. The other SNPs studied by Ishiguro et al (−203 and −710) were in highly significant and strong LD with each other and the Ser9Gly polymorphism. However, neither gave evidence for association either on their own or from haplotype analysis. Specifically, Ishiguro et al reported the greatest difference in the −710C, −203G, Gly9 haplotype which was more common in their control group.
11 Analysis of our sample in fact revealed a slightly increased frequency of this haplotype in the cases (0.2450 ± 0.0368) compared with the controls (0.2228 ± 0.0354). It seems unlikely therefore that these alleles in the putative promoter region of the DRD3 gene play any major role in the disease state of schizophrenia and that the differences in the haplotype distribution merely reflect the genetic structure of the populations under study.
The main objective of this study was to identify the promoter region of DRD3 and test SNPs in this region for LD with the Ser9Gly polymorphism that might account for other reports of association. Having detected no association with the SNPs or haplotypes of SNPs reported by Ishiguro et al, 11 we selected a further three SNPs in the promoter region (−6733G/A, −4147C/T and −2249G/A) to cover approximately 7 kb 5Ј to look for LD across this extended region and to look for disease association (Table 8) . We also genotyped a missense variant A38T that had been identified in exon 1 in case this had a significant effect in the UK sample. However, none of the SNPs yielded evidence supportive of association with schizophrenia. Clearly, since in this sample no evidence for association was found between schizophrenia and the Ser9Gly polymorphism, we cannot draw firm conclusions as to whether any of these other variants account for association with schizophrenia in other samples by virtue of linkage disequilibrium. However, we would note that with the exception of the −712G/C and −203G/A variants (Table 4) , the allele frequencies of the other SNPs and the Ser9Gly polymorphism are so incongruent making it unlikely that findings of association with the latter marker would pick up association as a result of the former.
In summary we have characterised the promoter region of DRD3 and tested the hypothesis that SNPs detected in this region that are in LD with the Ser9Gly
Molecular Psychiatry polymorphism play a role in susceptibility to developing schizophrenia. Although the promoter region was successfully characterised, we not only failed to show any association with SNPs contained therein and schizophrenia, we failed to replicate previous findings (including our own) that an excess of homozygosity at the Ser9Gly locus was associated with schizophrenia. The results from this study imply that neither the coding nor the regulatory regions of DRD3 plays a major role in predisposition to schizophrenia. However, our data on the genomic structure of DRD3 and the SNPs we have identified constitute important new reagents for further studies on the role of this gene in other forms of psychopathology.
